Wir sind mit live! Mehr erfahren

Steris

STE

Börsenwert 21,7 Mrd. $

222,66 USD

-1,67

0,74 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

222,66

0,00

0 %

1 Tag

-0,74 %

5 Tage

3,04 %

1 Monat

6,08 %

3 Monate

0,69 %

6 Monate

1,22 %

Seit Jahresbeginn

-10,95 %

1 Jahr

-7,34 %

5 Jahre

-0,24 %

10 Jahre

222,65 %

Profil: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.

Mitarbeiter: 17.937

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 42,9 %

Neutral 52,4 %

Negativ 4,8 %

Zacks Investment Research

Reasons to Add STE Stock to Your Portfolio Right Now

STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.

Reasons to Add STE Stock to Your Portfolio Right Now

Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)

PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting healthcare professionals, and delivering innovative solutions to the surgical environment.

Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)

Steris to Acquire Xodus Medical for $2.1 Billion

The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.

Steris to Acquire Xodus Medical for $2.1 Billion

STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

STERIS to Present at the Morgan Stanley Healthcare Conference

Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.

STERIS to Present at the Morgan Stanley Healthcare Conference

Zacks Investment Research

Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?

Zacks Investment Research

Should Investors Buy STERIS as Growth Meets Reasonable Valuation?

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Should Investors Buy STERIS as Growth Meets Reasonable Valuation?

STERIS Q1 Earnings Call Highlights

STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.

STERIS Q1 Earnings Call Highlights

STERIS plc (STE) Q1 2027 Earnings Call Transcript

STERIS plc (STE) Q1 2027 Earnings Call Transcript

STERIS plc (STE) Q1 2027 Earnings Call Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt